2/

#HIV has minimal influence on organ allocation in respondents, but is a significant barrier to the selection of a potential donor, even an appropriate recipient. Organ quality was the most influential factor in selection of a prospective donor.

100%

There was some really interesting data presented at #CROI2024 which explored racial disparities in the lifetime risk of acquiring HIV and highlighted some of those issues of intersectionality.

www.aidsmap.com/news/mar-202...

#HIVsky #IDsky

None, though I don’t have many people on injectables at this stage.

I think more will be inclined to switch, once LAI are Q6M, or can be self administered. (LEN + ? 👀)

Frequent clinical attendance and frequent injections seem major deterrents.

Cab-LA not yet funded as PrEP here either.

👍🏼

Same! (Plus Simva-, and Pravastatin, thou not sure why anyone would use these preferentially…)

We have:
Rosuvastatin 5-40mg
Atorvastatin 10-80mg

I typically start with rosuvastatin 10mg, unless pt on boosted PI (then typically half)

Do you have access to pitavastatin?

Interesting!

We use www.cvdcheck.org.au/calculator which is based on the NZ PREDICT-1° equation.

I mostly use it in conversations about risk and impact of risk factor modification (eg smoking cessation). None of our calculators incorporate HIV, ART, etc, and likely underestimate risk.

3/ #HIVinFocus

International guidelines recommend implementing the #Reprievestudy findings with different thresholds of #CVD risk statin therapy.

Australian guidance most closely aligns with the EACS recommendation.

2/ Australian CVD risk calculators typically assign a lower risk to #PWH than AHA/ACC score.

International guidelines recommend implementing this evidence differently.

6/ #REPRIEVEstudy also highlighted that #CVD risk calculators tend to overestimate CVD risk in developing countries, but underestimate risk in women.

5/ #REPRIEVEstudy showed that statins were safe (pitavastatin was chosen because it doesn’t interact with PIs), with a non-sig trend towards incident #diabetes, though glycaemic control was curiously unchanged.

4/ #REPRIEVEstudy demonstrated definitively that statins reduce CVD risk in people with #HIV 35% with low to moderate #ASCVD risk at baseline.

3/ mechanistically statins reduce CVD risk through several mechanisms; LDL lowering, plaque stabilization, dampening inflammation. Interestingly #REPRIEVEstudy proteomic analysis suggested PCOLCE may be important in pitavastatin impact on collagen deposition.

2/ importance of identifying and addressing lifestyle factors, social and psychological determinants of health to reduce #CVD risk